Emma Childs1, Joseph A Lutz2, Harriet de Wit2. 1. The University of Chicago, Department of Psychiatry Behavioral Neuroscience, 5841 S. Maryland Ave., MC3077, Chicago IL 60637, United States. Electronic address: echilds@psych.uic.edu. 2. The University of Chicago, Department of Psychiatry Behavioral Neuroscience, 5841 S. Maryland Ave., MC3077, Chicago IL 60637, United States.
Abstract
OBJECTIVES:Cannabis smokers often report that they use the drug to relax or to relieve emotional stress. However, few clinical studies have shown evidence of the stress-relieving effects of cannabis or cannabinoid agonists. In this study, we sought to assess the influence of delta-9-tetrahydrocannabinol (THC), a main active ingredient of cannabis, upon emotional responses to an acute psychosocial stressor among healthy young adults. METHODS:Healthy volunteers (N=42) participated in two experimental sessions, one withpsychosocial stress (Trier Social Stress Test, TSST) and another with a non-stressful task, after receiving 0 (N=13), 7.5mg (N=14) or 12.5mg (N=15) oral THC. Capsules were administered under randomized, double blind conditions, 2.5h before the tasks began. We measured subjective mood and drug effects, vital signs and salivary cortisol before and at repeated times after the capsule and tasks. Subjects also appraised the tasks, before and after completion. RESULTS: In comparison to placebo, 7.5mg THC significantly reduced self-reported subjective distress after the TSST and attenuated post-task appraisals of the TSST as threatening and challenging. By contrast, 12.5mg THC increased negative mood overall i.e., both before and throughout the tasks, and pre-task ratings of the TSST as threatening and challenging. It also impaired TSST performance and attenuated blood pressure reactivity to the stressor. CONCLUSIONS: Our findings suggest that a low dose of THC produces subjective stress-relieving effects in line with those commonly reported among cannabis users, but that higher doses may non-specifically increase negative mood.
RCT Entities:
OBJECTIVES: Cannabis smokers often report that they use the drug to relax or to relieve emotional stress. However, few clinical studies have shown evidence of the stress-relieving effects of cannabis or cannabinoid agonists. In this study, we sought to assess the influence of delta-9-tetrahydrocannabinol (THC), a main active ingredient of cannabis, upon emotional responses to an acute psychosocial stressor among healthy young adults. METHODS: Healthy volunteers (N=42) participated in two experimental sessions, one with psychosocial stress (Trier Social Stress Test, TSST) and another with a non-stressful task, after receiving 0 (N=13), 7.5mg (N=14) or 12.5mg (N=15) oral THC. Capsules were administered under randomized, double blind conditions, 2.5h before the tasks began. We measured subjective mood and drug effects, vital signs and salivary cortisol before and at repeated times after the capsule and tasks. Subjects also appraised the tasks, before and after completion. RESULTS: In comparison to placebo, 7.5mg THC significantly reduced self-reported subjective distress after the TSST and attenuated post-task appraisals of the TSST as threatening and challenging. By contrast, 12.5mg THC increased negative mood overall i.e., both before and throughout the tasks, and pre-task ratings of the TSST as threatening and challenging. It also impaired TSST performance and attenuated blood pressure reactivity to the stressor. CONCLUSIONS: Our findings suggest that a low dose of THC produces subjective stress-relieving effects in line with those commonly reported among cannabis users, but that higher doses may non-specifically increase negative mood.
Authors: H Valerie Curran; Catherine Brignell; Sally Fletcher; Paul Middleton; John Henry Journal: Psychopharmacology (Berl) Date: 2002-07-23 Impact factor: 4.530
Authors: Carrie Cuttler; Alexander Spradlin; Amy T Nusbaum; Paul Whitney; John M Hinson; Ryan J McLaughlin Journal: Psychopharmacology (Berl) Date: 2017-05-31 Impact factor: 4.530
Authors: Jennie E Ryan; Maia Noeder; Christine Burke; Samuel C Stubblefield; Salwa Sulieman; Elissa G Miller Journal: Pediatr Transplant Date: 2019-05-23
Authors: Stephanie C Reed; Margaret Haney; Jeanne Manubay; Bianca R Campagna; Brian Reed; Richard W Foltin; Suzette M Evans Journal: Pharmacol Biochem Behav Date: 2018-12-04 Impact factor: 3.533
Authors: Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2020-09-15 Impact factor: 4.147
Authors: Michael D Rizzo; Robert B Crawford; Joseph E Henriquez; Yasser A Aldhamen; Peter Gulick; Andrea Amalfitano; Norbert E Kaminski Journal: AIDS Date: 2018-02-20 Impact factor: 4.177